Prevalence of substance misuse in new patients in an outpatient psychiatry clinic using a prescription monitoring program

Prim Care Companion CNS Disord. 2014;16(1):PCC.13m01566. doi: 10.4088/PCC.13m01566. Epub 2014 Jan 2.

Abstract

Objective: To investigate the value of a prescription monitoring program in identifying prescription drug misuse among patients presenting to a resident physician outpatient psychiatry clinic at an academic medical center.

Method: Participants were 314 new patients aged 18 years or older presenting to the clinic from October 2011 to June 2012. Resident physicians completed a data collection form for each participant using information from the patient interview and from the prescription monitoring program report. Prescription drug misuse was defined as having any 1 of the following 5 criteria in the prescription monitoring program report: (1) filled prescriptions for 2 or more controlled substances, (2) obtained prescriptions from 2 or more providers, (3) obtained early refills, (4) used 3 or more pharmacies, and (5) the prescription monitoring program report conflicted with the patient's report.

Results: At least 1 indicator of prescription drug misuse was found in 41.7% of patients. Over 69% of the patients that the residents believed were misusing prescription drugs actually met 1 of the criteria for prescription drug misuse. The prescription monitoring program report changed the management only 2.2% of the time. Patients with prior benzodiazepine use (χ(2) 1 = 17.68, P < .001), prior opioid use (χ(2) 1 = 19.98, P < .001), a personality disorder (χ(2) 1 = 7.22, P < .001), and chronic pain (χ(2) 1 = 14.31, P < .001) had a higher percentage of prescription drug misuse compared to patients without these factors.

Conclusion: Using the prescription monitoring program to screen patients with prior benzodiazepine and opioid use, with a personality disorder, and/or with chronic pain may be useful in confirming the suspicion of prescription drug misuse identified at the initial evaluation.